Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kang-Fu-Yan capsules for chronic pelvic pain due to sequelae of pelvic inflammatory disease
ChiCTR1900022732Phase 4Completed
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- Sep 2014
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of kangfuyan in Pelviabdominal infection and chronic prostatitis (CP) (2 arms), sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoints: Improvement in main symptoms and Curative effect of the disease. Started Sep 2014; status: completed.
02
Drugs
kangfuyan
03
Conditions
Pelviabdominal infectionchronic prostatitis (CP)
Beyond the preview
Go deeper on ChiCTR1900022732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022732.